| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | -0.053 | 0.3 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.3 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.3 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.055 | 0.4 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.4 |